Deutsche Bank set a €99.00 ($115.12) price target on Sanofi (EPA:SAN) in a research report sent to investors on Wednesday, Borsen Zeitung reports. The firm currently has a buy rating on the stock.
SAN has been the subject of several other reports. UBS Group set a €89.50 ($104.07) target price on Sanofi and gave the stock a buy rating in a research note on Thursday, February 6th. Credit Suisse Group set a €105.00 ($122.09) price target on Sanofi and gave the stock a buy rating in a report on Friday, February 7th. JPMorgan Chase & Co. set a €103.00 ($119.77) price target on Sanofi and gave the stock a buy rating in a report on Wednesday. Goldman Sachs Group set a €100.00 ($116.28) price target on Sanofi and gave the stock a neutral rating in a report on Thursday, February 6th. Finally, HSBC set a €89.00 ($103.49) price target on Sanofi and gave the stock a neutral rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company’s stock. Sanofi presently has an average rating of Buy and a consensus target price of €98.35 ($114.36).
Shares of EPA SAN opened at €92.24 ($107.26) on Wednesday. Sanofi has a 12 month low of €63.09 ($73.36) and a 12 month high of €92.97 ($108.10). The stock has a 50 day moving average of €90.73 and a 200-day moving average of €83.67.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Recommended Story: What is a balanced fund?
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.